Go offline with the Player FM app!
From Injections to Pills: Breaking Down the New Oral GLP-1 Data
Manage episode 515214071 series 3363968
Show Notes:
In this episode of Docs Who Lift, the Nadolsky brothers welcome back Dr. Sean Wharton, clinical trialist and one of the leading researchers behind the next generation of oral GLP-1 medications. Together, they break down:
The OASIS-4 trial results on 25mg oral semaglutide and how it stacks up to injectable Wegovy
How orforglipron, Eli Lilly’s new small-molecule GLP-1, differs from peptide-based drugs
Why these new therapies could make weight management more accessible and affordable
The fascinating pharmacology behind “snack molecules” and small-molecule receptor agonists
Common misconceptions about bioavailability, dosing, and side effects
The potential role of oral GLP-1s for patients with mild obesity or cardiometabolic disease
Whether you’re a clinician, researcher, or patient curious about the future of obesity medicine, this conversation offers a clear look at how science is shifting toward needle-free solutions.
Oasis 1 Trial Link
Oasis 4 Trial Link
Attain 1 Trial Link
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
138 episodes
Manage episode 515214071 series 3363968
Show Notes:
In this episode of Docs Who Lift, the Nadolsky brothers welcome back Dr. Sean Wharton, clinical trialist and one of the leading researchers behind the next generation of oral GLP-1 medications. Together, they break down:
The OASIS-4 trial results on 25mg oral semaglutide and how it stacks up to injectable Wegovy
How orforglipron, Eli Lilly’s new small-molecule GLP-1, differs from peptide-based drugs
Why these new therapies could make weight management more accessible and affordable
The fascinating pharmacology behind “snack molecules” and small-molecule receptor agonists
Common misconceptions about bioavailability, dosing, and side effects
The potential role of oral GLP-1s for patients with mild obesity or cardiometabolic disease
Whether you’re a clinician, researcher, or patient curious about the future of obesity medicine, this conversation offers a clear look at how science is shifting toward needle-free solutions.
Oasis 1 Trial Link
Oasis 4 Trial Link
Attain 1 Trial Link
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
138 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.